For Patients With mCRPC, Results With Pluvicto in Real-World Settings Keep Pace With Clinical Trials

Why It Matters

The data validate Pluvicto’s effectiveness in everyday practice, supporting earlier use to postpone chemotherapy and informing payer and clinician decisions on sequencing mCRPC therapies.

Key Takeaways

• Real‑world median PFS 13.5 months, aligns with trial
• One prior ARPI yields 15.8‑month PFS, better than multiple ARPIs
• PSA₅₀ response ~62% across patient groups
• Majority completed all six Pluvicto doses, indicating tolerability
• Rural infrastructure limits nationwide access to radioligand therapy

Pulse Analysis

Pluvicto’s emergence as a radioligand therapy has reshaped the mCRPC landscape, offering a targeted approach that binds to prostate‑specific membrane antigen (PSMA) and delivers lethal radiation directly to tumor cells. While the FDA’s 2025 label expansion was based on the PSMAfore trial, clinicians have long awaited real‑world confirmation that efficacy translates beyond the controlled trial environment. The PRECISION database, encompassing over 56,500 metastatic prostate cancer cases, now provides that evidence, showing a median progression‑free survival (PFS) of 13.5 months that mirrors trial outcomes, and a robust PSA₅₀ response of roughly 62 %.

Beyond confirming efficacy, the real‑world analysis sheds light on optimal sequencing. Patients receiving Pluvicto after a single ARPI experienced a median PFS of 15.8 months, notably higher than the 12.7 months observed in those with multiple prior ARPIs. This suggests that earlier integration of the radioligand can maximize disease control while safely deferring taxane chemotherapy—a treatment associated with significant toxicity and quality‑of‑life trade‑offs. For oncologists, these findings reinforce a strategy of deploying Pluvicto promptly after ARPI failure, potentially redefining standard care pathways and influencing reimbursement models that traditionally favor stepwise escalation.

Nevertheless, the therapy’s promise is tempered by access disparities. While academic centers like Duke possess the nuclear‑medicine infrastructure required for safe administration, many rural hospitals lack the necessary facilities and multidisciplinary teams. This geographic gap forces patients to travel long distances, creating barriers that can delay treatment initiation. Stakeholders—including manufacturers, health systems, and policymakers—must explore mobile delivery units or tele‑supported hub‑and‑spoke models to broaden reach. As ongoing studies evaluate Pluvicto in earlier disease stages, ensuring equitable access will be crucial to fully realize its potential across the prostate‑cancer continuum.